Widely used in pharmaceutical research, this compound serves as a key intermediate in the synthesis of immunomodulatory drugs, particularly those targeting E3 ubiquitin ligase activity. It plays a critical role in the development of cereblon-binding molecules, which are essential for designing therapeutics in oncology, especially for hematological malignancies such as multiple myeloma and myelodysplastic syndromes. Its structure enables selective modulation of protein degradation pathways, making it valuable in PROTAC (proteolysis-targeting chimera) technology and targeted protein degradation research. Additionally, it is employed in structure-activity relationship (SAR) studies to optimize drug candidates for improved potency, selectivity, and pharmacokinetic properties.